FDA Determines Regulatory Review Period for SAPIEN 3 TRANSCATHETER HEART VALVE

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the SAPIEN 3 TRANSCATHETER HEART VALVE, as required by law, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).